| Sep 16 |
What Analysts Are Saying About Bristol-Myers Squibb Stock
|
| Sep 16 |
Bristol unveils 10-year Opdivo + Yervoy follow-up data in melanoma
|
| Sep 16 |
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
|
| Sep 16 |
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
|
| Sep 15 |
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
|
| Sep 15 |
Ten-year survival data show long-term benefit of immunotherapy in melanoma
|
| Sep 14 |
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
|
| Sep 13 |
ESMO 2024: BMS scores with ES-SCLC drug in patients with brain metastases
|
| Sep 12 |
With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
|
| Sep 12 |
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
|
